Back to our roots: Integrating wholistic research approaches in the study of medicinal plants and mushrooms
Melissa L. Perreault, T. Ryan Gregory, Andrew Maxwell Phineas Jones
Psychopharmacology April 24, 2026 DOI: 10.1007/s00213-026-07075-y (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Keywords | Medicinal plants Identification biology Traditional knowledge Medicinal fungi Traditional medicine Biotechnology |
| Key findings | The medicinal cannabis market is valued at over $21 billion in 2025 and projected to reach $116 billion by 2033, while the global psychedelic mushroom market is predicted to rise to $3.3 billion by 2031. |
Abstract
Whole plants and mushrooms have been used in systems of traditional medicine and health around the globe for millennia, and these more wholistic approaches are increasingly being embraced in modern Western societies. Cannabis and psilocybin are perhaps two of the most salient examples given current public and academic interests. Greater accessibility, along with expanding socioeconomic and environmental stress, and a growing body of literature supporting their therapeutic value, likely contribute to their expanding use in the general population. One recent report valued the medicinal cannabis market at over USD $21 billion in 2025, with a projected value of USD $116 billion by 2033 (Yadav 2025 ). Similarly, even though psychedelic mushrooms remain illegal in most regions, the global market is predicted to double in the next few years, rising to USD 3.3 billion by 2031 (Persistence Market Research, 2025 ) -- although it should be noted that, at present, it is not possible to delineate what portion of the market comes from use for medicinal purposes. There are many other examples of interest in whole plant/mushroom-based therapeutics including psychedelics such as ayahuasca, nootropics such as lion’s mane mushrooms, and other products used recreationally, to enhance performance, and/or with the intent to promote overall health.
Citations in the library
Cites 7
- Monoamine oxidase inhibitors in South American hallucinogenic plants: Tryptamine and β-carboline constituents of Ayahuasca Journal of Ethnopharmacology April 1, 1984
- Simultaneous Production of Psilocybin and a Cocktail of β‐Carboline Monoamine Oxidase Inhibitors in “Magic” Mushrooms Chemistry - A European Journal November 14, 2019
- Research on Acute Toxicity and the Behavioral Effects of Methanolic Extract from Psilocybin Mushrooms and Psilocin in Mice Toxins March 27, 2015
- Ethical Concerns about Psilocybin Intellectual Property ACS Pharmacology & Translational Science 2021
- A journey with psychedelic mushrooms: From historical relevance to biology, cultivation, medicinal uses, biotechnology, and beyond Biotechnology Advances August 31, 2023
and 2 more in the library